Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 59

1.

Multidisciplinary team conferences promote treatment according to guidelines in rectal cancer.

Brännström F, Bjerregaard JK, Winbladh A, Nilbert M, Revhaug A, Wagenius G, Mörner M.

Acta Oncol. 2015 Apr;54(4):447-53. doi: 10.3109/0284186X.2014.952387. Epub 2014 Oct 7.

PMID:
25291075
2.

Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: a nationwide population-based study in Sweden.

Eriksson H, Lyth J, Månsson-Brahme E, Frohm-Nilsson M, Ingvar C, Lindholm C, Naredi P, Stierner U, Wagenius G, Carstensen J, Hansson J.

Eur J Cancer. 2013 Aug;49(12):2705-16. doi: 10.1016/j.ejca.2013.03.013. Epub 2013 Apr 11.

PMID:
23583439
3.

Rapid expansion of T cells: Effects of culture and cryopreservation and importance of short-term cell recovery.

Sadeghi A, Ullenhag G, Wagenius G, Tötterman TH, Eriksson F.

Acta Oncol. 2013 Jun;52(5):978-86. doi: 10.3109/0284186X.2012.737020. Epub 2012 Nov 6.

PMID:
23126547
4.

Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark's level of invasion: results of a population-based study from the Swedish Melanoma Register.

Lyth J, Hansson J, Ingvar C, Månsson-Brahme E, Naredi P, Stierner U, Wagenius G, Lindholm C; Swedish Melanoma Study Group.

Br J Dermatol. 2013 Apr;168(4):779-86. doi: 10.1111/bjd.12095. Epub 2013 Jan 18.

5.

Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy.

Ullenhag GJ, Sadeghi AM, Carlsson B, Ahlström H, Mosavi F, Wagenius G, Tötterman TH.

Cancer Immunol Immunother. 2012 May;61(5):725-32. doi: 10.1007/s00262-011-1182-4. Epub 2011 Dec 23.

PMID:
22202906
6.

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group.

N Engl J Med. 2011 Jun 30;364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5.

7.

Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data.

Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA; ICBP Module 1 Working Group.

Lancet. 2011 Jan 8;377(9760):127-38. doi: 10.1016/S0140-6736(10)62231-3. Epub 2010 Dec 21.

8.

Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.

Hallqvist A, Wagenius G, Rylander H, Brodin O, Holmberg E, Lödén B, Ewers SB, Bergström S, Wichardt-Johansson G, Nilsson K, Ekberg L, Sederholm C, Nyman J.

Lung Cancer. 2011 Feb;71(2):166-72. doi: 10.1016/j.lungcan.2010.05.011. Epub 2010 Jun 11.

PMID:
20541833
9.

Social inequalities in non-small cell lung cancer management and survival: a population-based study in central Sweden.

Berglund A, Holmberg L, Tishelman C, Wagenius G, Eaker S, Lambe M.

Thorax. 2010 Apr;65(4):327-33. doi: 10.1136/thx.2009.125914.

PMID:
20388758
10.

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U; FLEX Study Team.

Lancet. 2009 May 2;373(9674):1525-31. doi: 10.1016/S0140-6736(09)60569-9.

PMID:
19410716
11.

How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group.

Nyman J, Friesland S, Hallqvist A, Seke M, Bergström S, Thaning L, Lödén B, Sederholm C, Wagenius G.

Lung Cancer. 2009 Jul;65(1):62-7. doi: 10.1016/j.lungcan.2008.10.021. Epub 2008 Dec 10.

PMID:
19081652
12.

Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma.

Bolander A, Agnarsdóttir M, Wagenius G, Strömberg S, Pontén F, Ekman S, Brattström D, Larsson A, Einarsson R, Ullenhag G, Hesselius P, Bergqvist M.

Melanoma Res. 2008 Dec;18(6):412-9. doi: 10.1097/CMR.0b013e328315c690.

PMID:
19011512
13.

Effector T cell analysis of melanoma tumor-infiltrating lymphocyte cultures using HLA-ABC semimatched melanoma cell lines.

Carlsson B, Sadeghi A, Bengtsson M, Wagenius G, Tötterman TH.

J Immunother. 2008 Sep;31(7):633-43. doi: 10.1097/CJI.0b013e3181822097.

PMID:
18600181
14.

Regional differences in treatment and outcome in non-small cell lung cancer: a population-based study (Sweden).

Myrdal G, Lamberg K, Lambe M, Ståhle E, Wagenius G, Holmberg L.

Lung Cancer. 2009 Jan;63(1):16-22. doi: 10.1016/j.lungcan.2008.05.011. Epub 2008 Jun 20.

PMID:
18571760
15.

The role of circulating angiogenic factors in patients operated on for localized malignant melanoma.

Bolander A, Wagenius G, Larsson A, Brattström D, Ullenhag G, Hesselius P, Ekman S, Bergqvist M.

Anticancer Res. 2007 Sep-Oct;27(5A):3211-7.

16.
17.

Physical exercise for cytotoxic drug-induced fatigue.

Hartvig P, Aulin J, Wallenberg S, Wagenius G.

J Oncol Pharm Pract. 2006 Dec;12(4):183-91.

PMID:
17156590
18.

Fatigue in cancer patients treated with cytotoxic drugs.

Hartvig P, Aulin J, Hugerth M, Wallenberg S, Wagenius G.

J Oncol Pharm Pract. 2006 Sep;12(3):155-64.

PMID:
17022870
19.

HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival.

Dreilich M, Wanders A, Brattström D, Bergström S, Hesselius P, Wagenius G, Bergqvist M.

Dis Esophagus. 2006;19(4):224-31.

PMID:
16866851
20.

Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.

Masucci GV, Månsson-Brahme E, Ragnarsson-Olding B, Nilsson B, Wagenius G, Hansson J.

Melanoma Res. 2006 Aug;16(4):357-63.

PMID:
16845332

Supplemental Content

Loading ...
Support Center